GSK Files 6-K on Own Share Transactions

TL;DR

**GSK is buying back its own stock, which is usually good news for shareholders.**

AI Summary

GSK plc filed a 6-K on March 26, 2026, reporting a "TRANSACTION IN OWN SHARES." This filing indicates that GSK is likely repurchasing its own stock, which can reduce the number of outstanding shares and potentially boost earnings per share. For investors, this matters because share buybacks often signal management's confidence in the company's valuation and can be a way to return value to shareholders, potentially increasing the stock price.

Why It Matters

This filing suggests GSK is actively managing its capital structure, which could lead to increased shareholder value through reduced share count and improved financial metrics.

Risk Assessment

Risk Level: low — A 6-K filing for 'TRANSACTION IN OWN SHARES' typically indicates a share buyback program, which is generally viewed positively by the market and carries low risk.

Analyst Insight

A smart investor would monitor GSK's future filings for details on the volume and frequency of these share transactions to gauge the extent of the buyback program and its potential impact on EPS.

Key Players & Entities

• GSK plc (company) — the filer of the 6-K
• 0001131399 (company) — GSK plc's CIK
• March 26, 2026 (date) — the filing and period of report date

Forward-Looking Statements

• GSK plc will continue its share repurchase program. (GSK plc) — medium confidence, target: 2026-12-31
• The share price of GSK plc may see a positive impact due to reduced share count. (GSK plc) — medium confidence, target: 2026-06-30

FAQ

Filing Documents

• a1561y.htm (6-K) — 3095KB
• 0001654954-26-002780.txt ( ) — 3096KB

From the Filing

IN OWN SHARES a1561y UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934       For the month of March 2026   Commission File Number 001-15170     GSK plc (Translation of registrant's name into English)     79 New Oxford Street, London, WC1A 1DG (Address of principal executive office)       Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F . . . .X. . . . Form 40-F . . . . . . . .           Transaction in own shares   GSK plc (the " Company ") announces today   acting through BNP Paribas SA (the " Broker "), it has purchased the following number of the Company's ordinary shares of  31¼  pence each.   Date of purchase: 25 March 2026 Aggregate number of ordinary shares of  31¼  pence each purchased: 345,000 Lowest price paid per share (GBp): 1,988.50p Highest price paid per share (GBp): 2,047.00p Volume-weighted average price paid per share (GBp): 2,033.20p   The purchased shares will be held   as Treasury shares.                                                                                                                            Such purchase forms part of the Company's existing buyback programme and was effected pursuant to the non-discretionary agreement entered into with the Broker, as announced on 17 February 2026. Since 17 February 2026, the Company has purchased 14,856,521 ordinary shares.   Following the above purchase, the Company will hold 254,747,615 ordinary shares in treasury and have 4,061,428,663 ordinary shares in issue (excluding Treasury shares).   The total number of voting rights in the Company is   4,061,428,663. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.   The Company confirms that, in accordance with DTR 5.5.1R, following the above purchase the percentage of voting rights attributable to the ordinary shares held in treasury is 6.27 per cent.   The table below contains detailed information of the individual trades made by the Broker on the London Stock Exchange and the CBOE Europe Limited recognised investment exchange (through its order books having market identification codes CHIX or BATE) as part of the buyback programme.   Schedule of Purchases Shares purchased:   GSK plc (ISIN: GB00BN7SWP63) Date of purchases:     25 March 2026 Investment firm:         BNP Paribas SA   Aggregated information per trading venue: Venue   Number of ordinary shares purchased   Highest price paid (per ordinary share)(GBp)   Lowest price paid (per ordinary share)(GBp)   Volume weighted average price paid (per ordinary share) (GBp)   BATE   32,194   2,047.00p   1,994.50p   2,035.49p   CHIX   65,953   2,047.00p   1,988.50p   2,033.60p   XLON   246,853   2,046.00p   1,991.50p   2,032.80p       Individual transactions: Number of Shares   Price per Share (GBp)   Trading venue   Date of transaction   Time of transaction   Transaction reference number   87   1991.5   XLON   25-Mar-2026   08:00:15   20260325181423813   70   1991.5   CHIX   25-Mar-2026   08:00:15   20260325181423815   97   1996.0   XLON   25-Mar-2026   08:01:00   20260325181425547   414   1996.0   XLON   25-Mar-2026   08:01:00   20260325181425551   195   199

View Full Filing

View this 6-K filing on SEC EDGAR